A randomized open-label phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
Brief description of study
If you have been diagnosed with advanced melanoma that has previously been treated or advanced melanoma that is unable to be surgically removed, you may qualify for this Phase 2 study. The main goal of this study is to evaluate how well spartalizumab in combination with LAG525, capmatinib, or canakinumab might work in treating patients with advanced melanoma.
Clinical Study Identifier: s18-00341
ClinicalTrials.gov Identifier: NCT03484923
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
